Marinus Pharmaceuticals, Inc. stock is up 42.16% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 December’s closed higher than November. 100% of analysts rate it a buy.
Marinus Pharmaceuticals, Inc. offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome.